New Therapeutic Strategies in Heart Failure

Joseph W. Rossano, John Jefferies, William J. Dreyer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This is an exciting time for the field of pediatric heart failure. While historically there has been little improvement in overall outcomes (Kantor et al., 2010; Towbin et al., 2006), there is the recent suggestion that both short-term and long-term outcomes may be improving (Wittlieb-Weber et al., 2015; Singh et al., 2014; Alexander et al., 2013). There are likely multiple factors that have contributed to this including the evolution and focus on pediatric heart failure as a distinct specialty within pediatric cardiology, improved medical management, and improved options for mechanical circulatory support. Moreover, there are many new promising therapies that will hopefully further improve heart failure outcomes for children in the coming decades. This chapter will focus on several of these therapies including regenerative therapy, new medications for acute and chronic therapy that are beneficial for adult heart failure patients (e.g., valsartan/sacubitril, ivabradine, serelaxin), and the next generation of ventricular assist devices.

Original languageEnglish (US)
Title of host publicationHeart Failure in the Child and Young Adult
Subtitle of host publicationFrom Bench to Bedside
PublisherElsevier
Pages565-574
Number of pages10
ISBN (Electronic)9780128026137
ISBN (Print)9780128023938
DOIs
StatePublished - Jan 1 2018

Fingerprint

Heart Failure
ivabradine
Pediatrics
Heart-Assist Devices
Therapeutics
Cardiology

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Rossano, J. W., Jefferies, J., & Dreyer, W. J. (2018). New Therapeutic Strategies in Heart Failure. In Heart Failure in the Child and Young Adult: From Bench to Bedside (pp. 565-574). Elsevier. https://doi.org/10.1016/B978-0-12-802393-8.00044-2

New Therapeutic Strategies in Heart Failure. / Rossano, Joseph W.; Jefferies, John; Dreyer, William J.

Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier, 2018. p. 565-574.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rossano, JW, Jefferies, J & Dreyer, WJ 2018, New Therapeutic Strategies in Heart Failure. in Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier, pp. 565-574. https://doi.org/10.1016/B978-0-12-802393-8.00044-2
Rossano JW, Jefferies J, Dreyer WJ. New Therapeutic Strategies in Heart Failure. In Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier. 2018. p. 565-574 https://doi.org/10.1016/B978-0-12-802393-8.00044-2
Rossano, Joseph W. ; Jefferies, John ; Dreyer, William J. / New Therapeutic Strategies in Heart Failure. Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier, 2018. pp. 565-574
@inbook{b6a472e3683e4998bd5e19e03b2de260,
title = "New Therapeutic Strategies in Heart Failure",
abstract = "This is an exciting time for the field of pediatric heart failure. While historically there has been little improvement in overall outcomes (Kantor et al., 2010; Towbin et al., 2006), there is the recent suggestion that both short-term and long-term outcomes may be improving (Wittlieb-Weber et al., 2015; Singh et al., 2014; Alexander et al., 2013). There are likely multiple factors that have contributed to this including the evolution and focus on pediatric heart failure as a distinct specialty within pediatric cardiology, improved medical management, and improved options for mechanical circulatory support. Moreover, there are many new promising therapies that will hopefully further improve heart failure outcomes for children in the coming decades. This chapter will focus on several of these therapies including regenerative therapy, new medications for acute and chronic therapy that are beneficial for adult heart failure patients (e.g., valsartan/sacubitril, ivabradine, serelaxin), and the next generation of ventricular assist devices.",
author = "Rossano, {Joseph W.} and John Jefferies and Dreyer, {William J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-802393-8.00044-2",
language = "English (US)",
isbn = "9780128023938",
pages = "565--574",
booktitle = "Heart Failure in the Child and Young Adult",
publisher = "Elsevier",
address = "Netherlands",

}

TY - CHAP

T1 - New Therapeutic Strategies in Heart Failure

AU - Rossano, Joseph W.

AU - Jefferies, John

AU - Dreyer, William J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This is an exciting time for the field of pediatric heart failure. While historically there has been little improvement in overall outcomes (Kantor et al., 2010; Towbin et al., 2006), there is the recent suggestion that both short-term and long-term outcomes may be improving (Wittlieb-Weber et al., 2015; Singh et al., 2014; Alexander et al., 2013). There are likely multiple factors that have contributed to this including the evolution and focus on pediatric heart failure as a distinct specialty within pediatric cardiology, improved medical management, and improved options for mechanical circulatory support. Moreover, there are many new promising therapies that will hopefully further improve heart failure outcomes for children in the coming decades. This chapter will focus on several of these therapies including regenerative therapy, new medications for acute and chronic therapy that are beneficial for adult heart failure patients (e.g., valsartan/sacubitril, ivabradine, serelaxin), and the next generation of ventricular assist devices.

AB - This is an exciting time for the field of pediatric heart failure. While historically there has been little improvement in overall outcomes (Kantor et al., 2010; Towbin et al., 2006), there is the recent suggestion that both short-term and long-term outcomes may be improving (Wittlieb-Weber et al., 2015; Singh et al., 2014; Alexander et al., 2013). There are likely multiple factors that have contributed to this including the evolution and focus on pediatric heart failure as a distinct specialty within pediatric cardiology, improved medical management, and improved options for mechanical circulatory support. Moreover, there are many new promising therapies that will hopefully further improve heart failure outcomes for children in the coming decades. This chapter will focus on several of these therapies including regenerative therapy, new medications for acute and chronic therapy that are beneficial for adult heart failure patients (e.g., valsartan/sacubitril, ivabradine, serelaxin), and the next generation of ventricular assist devices.

UR - http://www.scopus.com/inward/record.url?scp=85054945352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054945352&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802393-8.00044-2

DO - 10.1016/B978-0-12-802393-8.00044-2

M3 - Chapter

AN - SCOPUS:85054945352

SN - 9780128023938

SP - 565

EP - 574

BT - Heart Failure in the Child and Young Adult

PB - Elsevier

ER -